Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Oxygenta Pharmaceutical Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Option Chain
Analyzes market sentiment, predicts Oxygenta Pharmaceutical Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Oxygenta Pharma. - Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter Ended December 31, 2025.\r\n2
-
Oxygenta Pharmaceuti - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Oxygenta Pharmaceuti has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2025
-
Oxygenta Pharmaceuti - Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations,
-
Oxygenta Pharmaceuti - Minutes Of The Resolutions Passed By Way Of Postal Ballot
-
Oxygenta Pharmaceuti - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report
-
Oxygenta Pharmaceuti - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
-
Oxygenta Pharmaceuti - Intimation Of Calendar Of Events For The Postal Ballot Process Under Regulations 30 Of SEBI (Listing O
-
Oxygenta Pharmaceuti - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Oxygenta Pharmaceuti posts Q2 net loss of Rs 4.93 cr
-
Oxygenta Pharmaceuti - Announcement under Regulation 30 (LODR)-Change in Management
-
Oxygenta Pharmaceuti - Un Audited Financial Results For The Quarter And Half Year Ended 30.09.2025
-
Oxygenta Pharmaceuti - Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.11.2025
-
Oxygenta Pharmaceuti - Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter And Half Year Ended Septe
Key fundamentals
Evaluate the intrinsic value of Oxygenta Pharmaceutical Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 37.2076 | 37.1113 | 21.7934 | 17.4997 | 9.8685 |
| Liabilities | 37.2076 | 37.1113 | 21.7934 | 17.4997 | 9.8685 |
| Equity | 36.9835 | 33.4835 | 14.2013 | 14.2013 | 10.2013 |
| Gross Profit | -9.9947 | -9.6965 | -7.1168 | 1.4759 | 3.8424 |
| Net Profit | -9.6826 | -3.4793 | -11.5709 | -0.6104 | 2.9298 |
| Cash From Operating Activities | 2.6028 | -13.0496 | -1.6336 | -1.6799 | -1.6219 |
| NPM(%) | -8.85 | -8.77 | -37.34 | -1 | 5.63 |
| Revenue | 109.2986 | 39.6421 | 30.9874 | 60.5248 | 52.027 |
| Expenses | 119.2933 | 49.3386 | 38.1042 | 59.0488 | 48.1845 |
| ROE(%) | 26.39 | 9.48 | 31.54 | 1.66 | -7.98 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Oxygenta Pharmaceutical Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 703.00 | 2.24 | 0.00 | 34.63 | 301.39 | 0.71 |
| Lotus Eye Hospital and Institute Ltd | 123.40 | 1.36 | 381.94 | 126.19 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 19.46 | 1.41 | 0.00 | 262.02 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 599.35 | 2.22 | 0.00 | 119.00 | -604.77 | 0.00 |
Company Info
OXYGENTA PHARMACEUTICAL LIMITED was incorporated as Private Limited Company in the year 1990 and subsequently converted into a Limited Company in 1993, with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. 1990 - The company was incorporated and its main line of business was bulk drugs. 1994 - The company had entered into an MOU with ICD group BV of Netherlands. As per the agreement, ICD would purchase 36 tonnes a year of mebadazole and 12 tonnes of atenolol for a period of five years from the company. 1998 - The company was turned sick and was registered with BIFR. 2003 -The board of the company had approved to convert the unsecured loans of Rs 2 crore into 20 lakh equity shares of Rs 10 each. - The board had also proposed to increase the authorized capital to Rs 8 crore from the existing level of Rs 6 crore. 2006 - Mr. Y Ramachandra Reddy (joint managing director), Mr. E Rama Subba Reddy (director) and Mr. G Chandramoulieswar Reddy (director) had resigned from the board of directors of the company. 2007 - Board of directors of the company on 4th April had passed the resolution to extend the financial year of the company to 15 months. 2008 - The Board of the company had appointed Mr. MG Naidu as independent director of the company. 2022 -Company name has changed to Oxygenta Pharmaceutical Ltd. from S S Organics Ltd..
OXYGENTA PHARMACEUTICAL LIMITED was incorporated as Private Limited Company in the year 1990 and subsequently converted into a Limited Company in 1993, with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. 1990 - The company was incorporated and its main line of business was bulk drugs. 1994 - The company had entered into an MOU with ICD group BV of Netherlands. As per the agreement, ICD would purchase 36 tonnes a year of mebadazole and 12 tonnes of atenolol for a period of five years from the company. 1998 - The company was turned sick and was registered with BIFR. 2003 -The board of the company had approved to convert the unsecured loans of Rs 2 crore into 20 lakh equity shares of Rs 10 each. - The board had also proposed to increase the authorized capital to Rs 8 crore from the existing level of Rs 6 crore. 2006 - Mr. Y Ramachandra Reddy (joint managing director), Mr. E Rama Subba Reddy (director) and Mr. G Chandramoulieswar Reddy (director) had resigned from the board of directors of the company. 2007 - Board of directors of the company on 4th April had passed the resolution to extend the financial year of the company to 15 months. 2008 - The Board of the company had appointed Mr. MG Naidu as independent director of the company. 2022 -Company name has changed to Oxygenta Pharmaceutical Ltd. from S S Organics Ltd..
Read More
Parent Organisation
Oxygenta Pharmaceutical Ltd.
Founded
27/11/1990
Managing Director
NSE Symbol
FAQ
The current price of Oxygenta Pharmaceutical Ltd is
The 52-week high for Oxygenta Pharmaceutical Ltd is
The market capitalization of Oxygenta Pharmaceutical Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Oxygenta Pharmaceutical Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Oxygenta Pharmaceutical Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Oxygenta Pharmaceutical Ltd shares.
The CEO of Oxygenta Pharmaceutical Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
